INDIANAPOLIS, June 13, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved Olumiant (baricitinib), a once-daily pill, as a first-in-disease…Original Article
FDA Approves Lilly and Incyte’s Olumiant (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata
